Answers are grounded in this paper and cite their sources.
Overview highlights emerging therapies and their impact on BCG-unresponsive non-muscle-invasive bladder cancer treatment options.
Bacillus Calmette-Guérin (BCG) remains the cornerstone of therapy for high-risk non–muscle-invasive bladder cancer (NMIBC). However, up to 40% of patients develop BCG-unresponsive disease, where radical cystectomy remains the gold standard but is often unfeasible. During the past few years, multiple novel intravesical therapies have been developed, reshaping the management of BCG-unresponsive disease. The FDA approvals of pembrolizumab, nadofaragene firadenovec, BCG combined with the IL-15 superagonist N‑803, and the recently approved drug-delivery device TAR-200, alongside promising results of the oncolytic agent CG0070, mark a new era in bladder-sparing management. These therapies demonstrate clinically relevant efficacy with limited toxicity, redefining the treatment algorithm for BCG-unresponsive NMIBC.
No takes yet. Share an insight, caveat, or question.
Alfambra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: